A phase I/II clinical trial of immunotherapy with humanized MN-14 IgG [labetuzumab] in recurrent, metastatic, unresectable colorectal and breast carcinomas
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Labetuzumab (Primary)
- Indications Advanced breast cancer; Colorectal cancer
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 10 Sep 2005 New trial record.